European Universities Poised to Lead in Rare Disease Innovation Through New Funding Opportunity

The European Rare Diseases Research Alliance, known as ERDERA, has opened its Clinical Trial Call for 2026. This initiative supports multinational early-phase clinical trials focused on rare diseases, with a strong emphasis on academic leadership from universities across the continent. Researchers at higher education institutions are particularly well-positioned to form the consortia needed for these complex studies, which often involve small patient populations spread across multiple countries.

Universities in Europe have long been central to rare disease research, providing the expertise in genetics, pharmacology, and clinical trial design required for such work. The call specifically targets Phase I, Phase I/II, and Phase II interventional trials that comply with Good Clinical Practice standards. Priority areas include paediatric rare diseases, rapidly progressive conditions, and diseases lacking approved treatments or with significant unmet medical needs.

Understanding the Scope and Objectives of the 2026 Call

ERDERA's Clinical Trial Call aims to accelerate the development of new therapies by funding trials that generate robust clinical evidence. Academic teams at European universities can apply through a staged process that begins with a mandatory Expression of Interest. This structure encourages collaborative proposals involving multiple institutions, fostering cross-border partnerships that are essential for rare disease studies.

The call is designed to address the unique challenges of rare diseases, where traditional single-country trials are often impractical. By supporting multinational efforts, it aligns with the strengths of European higher education networks, where universities regularly collaborate on large-scale research projects funded by European Union programmes.

Key Dates and Application Stages for Academic Researchers

The call opened on 1 July 2026. Interested university research teams must submit an Expression of Interest between 1 July and 10 September 2026. Successful applicants then proceed to the Short Proposal stage, which runs from 15 September to 29 October 2026. An information webinar was held on 6 July 2026 to guide potential applicants through the requirements.

These timelines allow academic groups at universities sufficient time to assemble multinational consortia, secure necessary approvals, and prepare detailed proposals. Higher education institutions with established rare disease research centres are expected to play leading roles in coordinating these efforts.

How European Universities Can Participate and Benefit

University-based researchers are encouraged to lead or join consortia that include clinical partners, patient organisations, and other academic institutions. The call supports trials that can be conducted across borders, leveraging the diverse expertise found in European universities from different member states.

Participation offers significant benefits for higher education institutions, including enhanced research profiles, opportunities for PhD students and postdoctoral researchers to gain hands-on experience in clinical trials, and potential for long-term collaborations. Funding through this mechanism can also help universities attract additional grants and build capacity in rare disease research.

Photo by Nate Hughes on Unsplash

• Form multinational teams with complementary expertise
• Focus on priority areas such as paediatric conditions
• Ensure compliance with Good Clinical Practice from the outset
• Engage patient organisations early in the process

Impact on Academic Careers and Research Training

This funding opportunity directly supports career development in higher education. Early-career researchers at universities can gain valuable experience leading or contributing to international trials, strengthening their profiles for future faculty positions or independent grants.

PhD programmes and postdoctoral training at European universities stand to benefit as well. Students and fellows involved in funded trials will develop skills in trial design, regulatory affairs, and patient-centred research, preparing them for roles in academia, industry, or regulatory bodies.

Collaborative Networks and Institutional Partnerships

ERDERA encourages proposals that build on existing European research infrastructures. Universities already participating in networks focused on rare diseases are particularly well-placed to respond. The call promotes the formation of new alliances between institutions in different countries, enhancing the overall research ecosystem in higher education.

Such partnerships often lead to sustained collaborations beyond the initial trial, including joint publications, shared resources, and co-supervision of graduate students. This aligns with broader European efforts to strengthen research and innovation through university cooperation.

Challenges and Considerations for University Applicants

While the opportunity is significant, university teams must navigate the complexities of multinational trials, including varying regulatory environments and the need for harmonised protocols. Institutions with strong research support offices and experience in European-funded projects will have an advantage.

Academic leaders are advised to consult the detailed call text and pre-announcement documents available on the ERDERA website to ensure proposals meet all eligibility and evaluation criteria.

Future Outlook for Rare Disease Research in European Higher Education

The 2026 Clinical Trial Call represents a key step in advancing rare disease research within European universities. Successful trials could lead to new therapies, improved diagnostic approaches, and greater visibility for academic institutions involved.

Looking ahead, continued investment in such initiatives will be crucial for maintaining Europe's leadership in rare disease research. Universities that engage actively now are likely to shape the next generation of breakthroughs and attract top talent to their programmes.

Photo by Kix Chains on Unsplash

Resources and Next Steps for Interested Institutions

University researchers and administrators can access the full call details, draft texts, and registration for future webinars through the official ERDERA platform. Early engagement with potential partners across Europe is recommended to build competitive consortia.

Institutions should also explore internal funding mechanisms or national support programmes that can complement ERDERA grants, maximising the impact of their rare disease research portfolios.